Last reviewed · How we verify
NCT05948683: PEM
Prosocial Effects of MDMA
EARLY_PHASE1 trial testing MDMA in MDMA ('Ecstasy') in 33 participants. Completed in 15 July 2024.
15 July 2024
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 33 |
| Start date | 21 July 2023 |
| Primary completion | 15 July 2024 |
| Estimated completion | 15 July 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MDMA — full drug profile →
- Placebo
Conditions studied
- MDMA ('Ecstasy') — all drugs for MDMA ('Ecstasy') →
- Social Interaction — all drugs for Social Interaction →
Sponsor
University of Chicago
Who can join
Adults 18 to 35, any sex, with MDMA ('Ecstasy') or Social Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Can research on entactogens contribute to a deeper understanding of human sexuality?
Holka-Pokorska J. · · 2023 · cited 4× · PMID 37935915 · DOI 10.1007/s43440-023-00552-7
Verify or expand the search:
- PubMed search for NCT05948683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MDMA
Trials testing the same drug.
- NCT06353282 — MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents · Phase 2 · withdrawn
- NCT05746572 — MDMA Plus Exposure Therapy for PTSD · Phase 2 · enrolling by invitation
- NCT05943665 — MDMA for AUD/PTSD Comorbidity · Phase 2 · recruiting
- NCT05961527 — Group MDMA-therapy for Veterans With PTSD · Phase 1, PHASE2 · completed
- NCT05379959 — Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Funct · EARLY_PHASE1 · completed
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05948683 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 19 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05948683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing